- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| 15.10. | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 76 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 08.10. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates | 3 | GlobeNewswire (USA) | ||
| 26.09. | Impact BioMedical erhält neues US-Patent für Insektenschutzmittel | - | Investing.com Deutsch | ||
| 26.09. | Impact BioMedical secures new US patent for insect repellent | 1 | Investing.com | ||
| 26.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 93 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
| 20.09. | DSS Inc. buys $2,330 worth of Impact Biomedical shares | 1 | Investing.com | ||
| 19.09. | DSS Inc. buys Impact Biomedical shares worth over $150k | 2 | Investing.com | ||
| 17.09. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 170 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen | |
| 17.09. | Consumer wellness product developer Impact BioMedical prices IPO at $3 low end | 1 | Renaissance Capital | ||
| 16.09. | DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value | 109 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... ► Artikel lesen | |
| 16.09. | Impact BioMedical Prices 1.5 Mln IPO At $3 Per Share | 490 | AFX News | WASHINGTON (dpa-AFX) - Impact BioMedical Inc. (IBO), Monday announced the pricing of its initial public offering of 1.5 million shares at $3.00 per share. The offering is expected to close on... ► Artikel lesen | |
| 16.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces Pricing of Initial Public Offering | 196 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing... ► Artikel lesen | |
| 27.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.08. | IMPACT BIOMEDICAL INC. - 8-A12B/A, Registration of securities | 1 | SEC Filings | ||
| 20.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 7,270 | +4,01 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| TEMPUS AI | 34,650 | -0,74 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| SUMMIT THERAPEUTICS | 18,940 | +1,45 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ADMA BIOLOGICS | 17,390 | -1,86 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| EDGEWISE THERAPEUTICS | 29,660 | -1,07 % | Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains | ||
| 180 LIFE SCIENCES | 2,740 | +46,52 % | 180 Life Sciences Corp. - S-1/A, General form for registration of securities | ||
| JANUX THERAPEUTICS | 56,13 | -1,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,810 | -1,50 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,450 | +2,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies | ||
| ARCUTIS BIOTHERAPEUTICS | 14,980 | +0,07 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| NUVALENT | 82,83 | -1,22 % | Nuvalent-CEO Porter James Richard verkauft Aktien im Wert von 2,34 Millionen US-Dollar | ||
| ARCELLX | 77,10 | +0,40 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| ALPHA TEKNOVA | 8,615 | +12,17 % | Alpha Teknova Stock Hits 52-Week High at $8.93 Amid Growth Surge | ||
| NEUMORA THERAPEUTICS | 10,745 | -3,37 % | Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3% - Should You Sell? | ||
| HUMACYTE | 4,525 | -2,69 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen |
IMPACT BIOMEDICAL INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,385 Euro und damit -5,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.
